Empagliflozin gets positive CHMP decision for heart failure
medwireNews: Empagliflozin is on track to expand its indication in the EC to include heart failure, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).
The expanded indication will cover adults with symptomatic heart failure with reduced ejection fraction, irrespective of the presence of type 2 diabetes.
It follows the 2020 publication of the EMPEROR-Reduced trial, which found a significant 25% reduction in the risk for death from cardiovascular causes or hospitalization for heart failure with empagliflozin versus placebo in this patient group.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group